These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 7858534

  • 21. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [Abstract] [Full Text] [Related]

  • 22. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [Abstract] [Full Text] [Related]

  • 23. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [Abstract] [Full Text] [Related]

  • 24. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E.
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [Abstract] [Full Text] [Related]

  • 25. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [Abstract] [Full Text] [Related]

  • 26. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN.
    Bone Marrow Transplant; 2000 Feb; 25(3):257-62. PubMed ID: 10673696
    [Abstract] [Full Text] [Related]

  • 27. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 28. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
    [Abstract] [Full Text] [Related]

  • 29. Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
    Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF.
    J Clin Oncol; 1994 Sep; 12(9):1890-901. PubMed ID: 7916039
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 31. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P, Milpied N, Voillat L, Colombat P, Mahé B, Rapp MJ, Moreau A, Dupas B, Bulabois CE, Juge-Morineau N, Harousseau JL.
    Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
    [Abstract] [Full Text] [Related]

  • 32. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
    Broun ER, Nichols CR, Mandanas R, Salzman D, Turns M, Hromas R, Cornetta K, Einhorn LH.
    Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
    [Abstract] [Full Text] [Related]

  • 33. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
    Carlson K, Smedmyr B, Hagberg H, Oberg G, Simonsson B.
    Bone Marrow Transplant; 1993 Mar; 11(3):205-8. PubMed ID: 8467284
    [Abstract] [Full Text] [Related]

  • 34. Trial of high-dose cytarabine, cyclophosphamide, total-body irradiation, and autologous marrow transplantation for refractory lymphoma.
    Armitage JO, Gingrich RD, Klassen LW, Bierman PJ, Kumar PP, Weisenburger DD, Smith DM.
    Cancer Treat Rep; 1986 Jul; 70(7):871-5. PubMed ID: 3521847
    [Abstract] [Full Text] [Related]

  • 35. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.
    Demirer T, Weaver CH, Buckner CD, Petersen FB, Bensinger WI, Sanders J, Clift RA, Lilleby K, Anasetti C, Martin P.
    J Clin Oncol; 1995 Mar; 13(3):596-602. PubMed ID: 7884421
    [Abstract] [Full Text] [Related]

  • 36. Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia.
    Meloni G, De Fabritiis P, Pulsoni A, Sandrelli A, Giona F, Simone F, Mandelli F.
    Haematologica; 1989 Mar; 74(1):67-70. PubMed ID: 2498186
    [Abstract] [Full Text] [Related]

  • 37. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
    Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D.
    J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
    [Abstract] [Full Text] [Related]

  • 38. [Treatment of resistant or relapsing Hodgkin's disease with high doses of chemotherapy followed by autologous bone marrow transplant].
    Domingo-Albós A, García J, Puig J, Brunet S, Ayats R, Pardo N, Soler J, Muñiz E, Badell I.
    Med Clin (Barc); 1990 Mar 10; 94(9):321-4. PubMed ID: 2329865
    [Abstract] [Full Text] [Related]

  • 39. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan 10; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 40. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D.
    Cancer Treat Rep; 1987 Feb 10; 71(2):119-25. PubMed ID: 3542208
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.